Characteristics | BV (n, %) | EV (n, %) | GO (n, %) | IO (n, %) | MS (n, %) | PV (n, %) | SG (n, %) | TD (n, %) | TE (n, %) | In total (n, %) |
---|---|---|---|---|---|---|---|---|---|---|
Gender | 137(9.04) | 209(13.80) | 22(1.45) | 30(1.98) | 54(3.56) | 80(5.27) | 183(12.06) | 764(50.36) | 38(2.50) | 1517 |
Famale | 42(4.57) | 43(4.68) | 11(1.20) | 10(1.09) | 34(3.70) | 28(3.05) | 160(17.41) | 558(60.72) | 33(3.60) | 919 |
Male | 52(14.10) | 162(43.90) | 8(2.17) | 15(4.07) | - | 33(8.94) | 20(5.42) | 79(21.41) | - | 369 |
Unknown | 43(18.78) | 4(1.75) | 3(1.31) | 5(2.18) | 20(8.73) | 19(8.30) | 3(1.31) | 127(55.46) | 5(2.18) | 229 |
Age | ||||||||||
<18 | 1(25.00) | - | - | 3(75.00) | - | - | - | - | - | 4 |
18 ~ 65 | 47(11.46) | 45(10.98) | 14(3.41) | 11(2.68) | 3(0.73) | 14(3.41) | 77(18.78) | 184(44.88) | 15(3.66) | 410 |
>65 | 25(6.74) | 131(35.31) | 4(1.08) | 8(2.16) | - | 50(13.48) | 27(7.28) | 119(32.01) | 7(1.89) | 371 |
Unknown | 64(8.74) | 33(4.51) | 4(0.55) | 8(1.10) | 51(6.97) | 16(2.20) | 79(10.79) | 461(62.98) | 16(2.20) | 732 |
average | 55.89 | 72.51 | 53.06 | 49.10 | 57.67 | 71.17 | 57.90 | 60.29 | 59.59 | 59.69 |
Reporting Country | ||||||||||
US | 53(9.43) | 37(6.58) | - | 9(1.60) | 52(9.25) | 5(0.89) | 24(4.27) | 369(65.66) | 13(2.31) | 562 |
JP | 24(6.05) | 137(34.51) | - | 11(2.77) | - | 59(14.86) | - | 158(39.80) | 8(2.02) | 397 |
FR | 9(7.76) | 8(6.90) | 3(2.59) | - | - | - | 60(51.72) | 36(31.03) | - | 116 |
DE | 16(39.02) | 1(2.44) | 1(2.44) | 2(4.88) | - | - | 5(12.20) | 16(39.02) | - | 41 |
CA | - | - | - | - | - | - | 15(11.72) | 113(88.28) | - | 128 |
Others | 35(12.82) | 26(9.53) | 18(6.59) | 8(2.93) | 2(0.73) | 16(5.86) | 79(28.94) | 72(26.37) | 17(6.23) | 273 |
Indications | ||||||||||
hodgkin’s disease | 80(100.00) | - | - | - | - | - | - | - | - | 80 |
lymphoma | 34(26.77) | - | - | 15(11.81) | - | 78(61.42) | - | - | - | 127 |
unknown | 3(1.63) | - | 4(2.17) | 13(7.07) | 36(19.57) | 2(1.09) | 21(11.41) | 99(53.80) | 6(3.26) | 184 |
transitional cell carcinoma | - | 127(100.00) | - | - | - | - | - | - | - | 127 |
bladder cancer | - | 43(87.76) | - | - | - | - | 6(12.24) | - | - | 49 |
acute myeloid leukemia | - | - | 18(90.00) | 2(10.00) | - | - | - | - | - | 20 |
ovarian cancer | - | - | - | - | 18(100.00) | - | - | - | - | 18 |
breast cancer | - | - | - | - | - | - | 131(20.22) | 531(77.63) | 22(3.22) | 684 |
gastric cancer | - | - | - | - | - | - | - | 82(100.00) | - | 82 |
Other | 30(22.06) | 39(28.68) | - | - | - | - | 25(18.38) | 52(38.24) | - | 136 |
Outcome | ||||||||||
Death | 18(7.59) | 41(17.30) | 4(1.69) | 7(2.95) | - | 20(8.44) | 37(15.61) | 97(40.93) | 13(5.49) | 237 |
Hospitalization initial or prolonged | 67(15.26) | 96(21.87) | 5(1.14) | 4(0.91) | 10(2.28) | 26(5.92) | 84(19.13) | 138(31.44) | 9(2.05) | 439 |
Life-threatening | 10(23.26) | 11(25.58) | 4(9.30) | 1(2.33) | - | 5(11.63) | 5(11.63) | 7(16.28) | - | 43 |
Other | 37(6.75) | 61(11.13) | 9(1.64) | 16(2.92) | 16(2.92) | 27(4.93) | 52(9.49) | 314(57.30) | 16(2.92) | 548 |
Unknown | 5(2.00) | - | - | 2(2.00) | 28(11.20) | 2(2.00) | 5(5.00) | 208(83.20) | - | 250 |